Oncolytics Biotech (Oncolytics Biotech) EBIT : $-25.07 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech EBIT?

Oncolytics Biotech's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-6.60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.07 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Oncolytics Biotech's annualized ROC % for the quarter that ended in Dec. 2023 was -954.87%. Oncolytics Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -5,083.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Oncolytics Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -44.13%.

Oncolytics Biotech EBIT Historical Data

The historical data trend for Oncolytics Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech EBIT Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-15.47

-19.88

-20.50

-19.82

-25.19

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-6.26	-4.92	-5.39	-8.17	-6.60

Competitive Comparison of Oncolytics Biotech's EBIT

For the Biotechnology subindustry, Oncolytics Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's EV-to-EBIT falls into.

Oncolytics Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.07 Mil.

Oncolytics Biotech (NAS:ONCY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Oncolytics Biotech's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-26.384 * ( 1 - -1.1% )	/	( (4.608	+	0.979)	/ 2 )
=	-26.674224	/	2.7935
=	-954.87 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.062	-	3.352	-	( 29.548	-	max(0, 7.404	-	33.506	+	29.548	))
=	4.608

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.936	-	2.662	-	( 26.023	-	max(0, 3.158	-	28.453	+	26.023	))
=	0.979

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Oncolytics Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-26.384	/	( ( (0.556 + max(-3.771, 0))	+	(0.482 + max(-0.64, 0)) )	/	2 )
=	-26.384	/	( ( 0.556	+	0.482 )	/	2 )
=	-26.384	/	0.519
=	-5,083.62 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.492)	-	(3.352	+	0	+	3.911)
=	-3.771

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.419)	-	(2.662	+	0	+	0.397)
=	-0.64

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Oncolytics Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-25.071	/	56.810
	=	-44.13 %

Oncolytics Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.